45 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
% of patients exposed to IBRANCE across PALOMA-2 and PALOMA-3. One death due to neutropenic sepsis was observed in PALOMA-3. Inform patients to promptly report
S-8
EX-99.3
ARVN
Arvinas Inc
16 Jan 24
Registration of securities for employees
4:03pm
) Exercise Period Upon Death or Disability. If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior … in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant
8-K
EX-99.1
7ck dq98ft9582
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-3.1
l8uoi3whxefcbsab qa
21 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:32pm
8-K
urt2c7
16 Dec 22
Arvinas Announces Changes to its Board of Directors
9:02am
8-K
pl22q46s ig6o1slocw
19 Aug 22
Departure of Directors or Certain Officers
9:15am
8-K
EX-99.1
ijnqgzzmuu
10 Dec 21
Regulation FD Disclosure
8:16am
8-K
EX-99.2
jcm167
10 Dec 21
Regulation FD Disclosure
8:16am
8-K
EX-99.1
unkxjb 41fvn2axt
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
424B5
wmg3okumjoa
16 Dec 20
Prospectus supplement for primary offering
4:01pm
424B5
zgkka
14 Dec 20
Prospectus supplement for primary offering
4:48pm